









Markets
/
Stocks
/
nasdaq-legn
/

Legend Biotech Corp

LEGN

34.010USD

-1.150-3.27%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

6.28BMarket Cap

LossP/E TTM



Legend Biotech Corp

34.010

-1.150-3.27%

Overview Company Financials Analysis

Analysis

More Details of Legend Biotech Corp Company

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Company Info

Ticker SymbolLEGN

Company nameLegend Biotech Corp

IPO dateJun 04, 2020

CEODr. Ying Huang, Ph.D.

Number of employees2600

Security typeDepository Receipt

Fiscal year-endJun 04

Address2101 Cottontail Lane

CitySOMERSET

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code08873

Phone17328505598

Websitehttps://investors.legendbiotech.com/

Ticker SymbolLEGN

IPO dateJun 04, 2020

CEODr. Ying Huang, Ph.D.

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Ye (Sally) Wang

Director

84.32K

Dr. Li Mao

Independent Director

7.62K

Dr. Li Zhu, Ph.D.

Director

4.20K

Mr. Xiaohui (Darren) Ji

Independent Director

Ms. Jessie Yeung

Director

Dr. Peter Salovey, Ph.D.

Independent Director

Mr. Wai Man (Philip) Yau, CPA

Independent Director

Dr. Ying Huang, Ph.D.

Chief Executive Officer, Director

-100.00%

Mr. Tomas J. (Tom) Heyman, Jr.

Independent Director

Dr. Fangliang (Frank) Zhang, Ph.D.

Chairman of the Board

Name

Name/Position

Position

Shareholding

Change

Ms. Ye (Sally) Wang

Director

84.32K

Dr. Li Mao

Independent Director

7.62K

Dr. Li Zhu, Ph.D.

Director

4.20K

Mr. Xiaohui (Darren) Ji

Independent Director

Ms. Jessie Yeung

Director

Dr. Peter Salovey, Ph.D.

Independent Director

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

No Data

By RegionUSD

Name

Revenue

Proportion

United States

168.29M

86.28%

Europe

26.67M

13.67%

China

90.00K

0.05%

By Business

By Region

No Data

Shareholding Stats

Updated: Fri, Aug 15

Shareholders

Shareholder Types

Shareholders

Proportion

Fidelity Management & Research Company LLC

12.53%

Westfield Capital Management Company, L.P.

3.51%

HHLR Advisors, Ltd.

3.36%

Suvretta Capital Management, LLC

2.04%

Deerfield Management Company, L.P.

1.60%

Other

76.95%

Shareholders

Proportion

Fidelity Management & Research Company LLC

12.53%

Westfield Capital Management Company, L.P.

3.51%

HHLR Advisors, Ltd.

3.36%

Suvretta Capital Management, LLC

2.04%

Deerfield Management Company, L.P.

1.60%

Other

76.95%

Shareholder Types

Shareholders

Proportion

Investment Advisor

22.27%

Investment Advisor/Hedge Fund

13.72%

Hedge Fund

8.80%

Corporation

1.22%

Research Firm

1.12%

Venture Capital

0.59%

Pension Fund

0.37%

Bank and Trust

0.31%

Sovereign Wealth Fund

0.20%

Other

51.40%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

545

89.45M

48.54%

-25.68M

2025Q1

566

91.15M

49.68%

-26.78M

2024Q4

546

104.37M

56.89%

-4.12M

2024Q3

521

96.19M

52.43%

-11.10M

2024Q2

501

96.66M

52.77%

-1.31M

2024Q1

490

91.55M

50.22%

-3.47M

2023Q4

482

91.08M

50.06%

-4.11M

2023Q3

468

90.50M

49.93%

-2.81M

2023Q2

459

88.99M

49.23%

+9.84M

2023Q1

421

72.14M

43.70%

-3.07M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Fidelity Management & Research Company LLC

11.26M

6.11%

-452.89K

-3.87%

Mar 31, 2025

Westfield Capital Management Company, L.P.

6.92M

3.75%

+1.20M

+21.07%

Mar 31, 2025

HHLR Advisors, Ltd.

5.98M

3.25%

Mar 31, 2025

Suvretta Capital Management, LLC

3.75M

2.03%

+253.73K

+7.26%

Mar 31, 2025

Deerfield Management Company, L.P.

1.74M

0.95%

+191.84K

+12.36%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.11M

1.69%

-148.24K

-4.55%

Mar 31, 2025

Braidwell LP

2.98M

1.62%

Mar 31, 2025

Fidelity Institutional Asset Management

1.95M

1.06%

+210.09K

+12.08%

Mar 31, 2025

Genscript Biotech Corp

2.25M

1.22%

Dec 31, 2024

Related ETFs

Updated: Sat, Sep 6

Name

Proportion

Xtrackers MSCI All China Equity ETF

SPDR MSCI ACWI ex-US ETF

Virtus LifeSci Biotech Products ETF

iShares MSCI Emerging Markets Asia ETF

SPDR S&P China ETF

SPDR MSCI Emerging Markets Fossil Fuel Reserves Free ETF

Xtrackers MSCI Em Mkts Hdg Eqty ETF

SPDR S&P Emerging Asia Pacific ETF

Xtrackers MSCI All Wld x US Hdg Eqty ETF

Xtrackers MSCI All China Equity ETF

Proportion0%

SPDR MSCI ACWI ex-US ETF

Proportion0%

Virtus LifeSci Biotech Products ETF

Proportion0%

iShares MSCI Emerging Markets Asia ETF

Proportion0%

SPDR S&P China ETF

Proportion0%

SPDR MSCI Emerging Markets Fossil Fuel Reserves Free ETF

Proportion0%

Xtrackers MSCI Em Mkts Hdg Eqty ETF

Proportion0%

SPDR S&P Emerging Asia Pacific ETF

Proportion0%

Xtrackers MSCI All Wld x US Hdg Eqty ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

KeyAI

